• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.

作者信息

Yam Charmaine, Fok Anthony, Mclean Catriona, Butler Ernest, Kempster Peter

机构信息

Department of Neuroscience, Alfred Health, Melbourne, Victoria, Australia.

Department of Neuroscience, Monash Health, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2019 Feb;49(2):274-276. doi: 10.1111/imj.14204.

DOI:10.1111/imj.14204
PMID:30754081
Abstract
摘要

相似文献

1
Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.β-干扰素在多发性硬化症中引发血栓性微血管病。
Intern Med J. 2019 Feb;49(2):274-276. doi: 10.1111/imj.14204.
2
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.干扰素β-1a治疗多发性硬化症所致的肾血栓性微血管病。
Drug Des Devel Ther. 2013 Aug 7;7:723-8. doi: 10.2147/DDDT.S42138. eCollection 2013.
3
Comment on thrombotic microangiopathy induced by interferon-β therapy.
Clin Nephrol. 2012 Dec;78(6):506-7. doi: 10.5414/cn107623.
4
Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.长期使用干扰素-β治疗多发性硬化症所致血栓性微血管病：一例报告
Clin Nephrol. 2011 Nov;76(5):396-400. doi: 10.5414/cn106523.
5
[Interferon ß, nephrotic syndrome and thrombotic microangiopathy].[干扰素β、肾病综合征与血栓性微血管病]
Med Clin (Barc). 2015 Jan 20;144(2):65-6. doi: 10.1016/j.medcli.2014.09.008. Epub 2014 Nov 20.
6
Thrombotic microangiopathy associated with interferon beta.与β-干扰素相关的血栓性微血管病
N Engl J Med. 2014 Mar 27;370(13):1270-1. doi: 10.1056/NEJMc1316118.
7
Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis.长期使用β-1b干扰素治疗多发性硬化症后出现肠道受累的血栓性微血管病
Intern Med. 2018 Mar 1;57(5):741-744. doi: 10.2169/internalmedicine.9326-17. Epub 2017 Nov 20.
8
Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.一名接受干扰素-β治疗多发性硬化症的男性因获得性补体因子I缺乏症导致血栓性微血管病。
Br J Clin Pharmacol. 2023 May;89(5):1682-1685. doi: 10.1111/bcp.15631. Epub 2022 Dec 23.
9
Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature.一名多发性硬化症患者接受15年β-1b干扰素治疗后发生血栓性微血管病：病例报告及文献复习
Intern Med. 2024 Apr 15;63(8):1113-1117. doi: 10.2169/internalmedicine.1846-23. Epub 2023 Sep 1.
10
Thrombotic microangiopathy and accelerated hypertension after treatment with interferon beta.
Nefrologia (Engl Ed). 2018 Sep-Oct;38(5):564-565. doi: 10.1016/j.nefro.2017.11.018. Epub 2018 Feb 9.

引用本文的文献

1
Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment-A Literature Review.血栓性微血管病作为多发性硬化症长期β-干扰素治疗的一种危及生命的并发症：临床表型及治疗反应——文献综述
J Clin Med. 2024 Mar 11;13(6):1598. doi: 10.3390/jcm13061598.
2
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.醋酸格拉替雷和干扰素β-1a治疗多发性硬化症患者的不良副作用：病例报告的系统评价
Curr J Neurol. 2023 Apr 4;22(2):115-136. doi: 10.18502/cjn.v22i2.13340.
3
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review.
多发性硬化症患者使用干扰素-β后迟发性非典型溶血尿毒综合征 1 例报告：文献复习中的开放性问题。
Brain Behav. 2021 Jan;11(1):e01930. doi: 10.1002/brb3.1930. Epub 2020 Dec 16.
4
Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature.干扰素相关肾病的广泛谱系——肾小球肾炎、系统性红斑狼疮样综合征和血栓性微血管病：一例病例报告及文献综述
World J Nephrol. 2019 Nov 12;8(7):109-117. doi: 10.5527/wjn.v8.i7.109.